ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Densem, C. G.
Right arrow Articles by Brooks, N. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Densem, C. G.
Right arrow Articles by Brooks, N. H.
Related Collections
Right arrow Transplantation - heart

Ann Thorac Surg 2004;77:875-880
© 2004 The Society of Thoracic Surgeons

Original article: cardiovascular

Influence of IFN-{gamma} polymorphism on the development of coronary vasculopathy after cardiac transplantation

Cameron G. Densem, MRCPa*, Ian V. Hutchinson, BSc, PhDb, Nizar Yonan, FRCSb, Nicholas H. Brooks, FRCPa

a Cardiothoracic Transplant Unit, Wythenshawe Hospital, United Kingdom
b and School of Biological Sciences, Manchester University, Manchester, United Kingdom

Accepted for publication July 30, 2003.

* Address reprint requests to Dr Densem, Department of Cardiology, Wythenshawe Hospital, Southmoor Rd, Wythenshawe, Manchester M23 9LT, UK
e-mail: cameron.d{at}virgin.net

BACKGROUND: The development of coronary vasculopathy (CV) limits survival after cardiac transplantation. Interferon (IFN)-{gamma} is an important immunomodulator affecting the growth and function of T cells and macrophages, free radical formation, adhesion molecule, and MHC class I and II expression, which are important processes for CV formation. IFN-{gamma} is expressed early after transplantation and neutralization or genetic absence of the cytokine can abrogate CV development. The expression of IFN-{gamma} is influenced by a dinucleotide repeat in the first intron of the IFN-{gamma} gene. We investigated the effect of this polymorphism on the development of CV.

METHODS: Using sequence specific primers to the IFN-{gamma} polymorphic region, polymerase chain reaction (PCR) and gel electrophoresis identified the genotype in 144 cardiac transplant recipients and 134 donors. An association was sought between the presence of a high, intermediate or low IFN-{gamma} producing genotype and the development of CV diagnosed by routine surveillance posttransplant angiography.

RESULTS: High, intermediate, and low IFN-{gamma} producers made up 29.2%, 44.4%, 26.4% and 24.6%, 40.3%, 35.1% of recipients and donors respectively (p = NS). IFN-{gamma} polymorphism in cardiac graft recipients had no impact on the time to first diagnosis of CV; high producers 4.03 years (± 129.9 days), intermediate producers 3.40 years (± 79.7 days), low producers 4.01 years (± 102.9 days); p = 0.16. Similar results were found on investigating donor polymorphism; high producers (3.68 years ± 120.1 days), intermediate producers (3.83 years ± 105.9 days), low producers (3.3 years ± 77.7 days); p = 0.35. Multivariate analysis identified the number of rejection episodes of ISHLT grade 3 or greater and increasing donor age to be independent risk factors for CV development.

CONCLUSIONS: Dinucleotide repeat polymorphism in the first intron of the human IFN-{gamma} gene does not influence CV development and cannot be used as a genetic risk marker.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2004 by The Society of Thoracic Surgeons.